Pharmacovigilance and Drug Safety
Win Medica’s goal is to safeguard patients and promote Health through continuous monitoring of its pharmaceutical safety data.
Pharmacovigilance, through the recording and reporting of adverse reactions to the competent authorities, contributes to enriching knowledge on the safety of medicines and uses all appropriate measures for their more appropriate and safer use. It shall continuously monitor the risk-benefit balance of medicinal products, ensuring that it remains positive in terms of benefit.
Checking the safety profile of all pharmaceutical products during their time on the market is vital.
In order to ensure this, Win Medica has the appropriate control systems in place to ensure that all sources of information are systematically checked, appropriate action is taken when new information becomes available and Competent Authorities, Healthcare Professionals and patients are informed of any changes in product characteristics.
Please report any adverse reactions experienced by your patients who receive the Company’s products as shown on the Products page.
When reporting, please provide as much information as possible, including information regarding medical history, any co-administration of another medication, and dates of occurrence and treatment.
For any suspected adverse reactions, please report them to the company by phone at 210 74 88 821 or by fax at 210 74 88 827 or by email at firstname.lastname@example.org .
For any medical information, please contact the company by phone at 210 74 88 821 or by e-mail at email@example.com
Keep in mind that adverse reactions associated with the use of the Company’s products as they appear on the Products page.
According to the National Agency for Medicines (EOF), you can report an adverse reaction can be reported by submitting the Yellow Card in the following ways:
Any notification can be important!
Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα, συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ".